Telehealth firm Hims & Hers began selling a compounded version of Novo Nordisk’s newly approved Wegovy pill, prompting immediate regulatory and industry backlash. The move has drawn public criticism from FDA leadership and legal threats from drugmakers, who argue the product undermines safety and intellectual property protections. FDA Commissioner Marty Makary publicly warned against mass marketing of unapproved copycat GLP-1 products and signaled the agency would “take swift action” against firms promoting illegal therapeutics. Novo Nordisk and other manufacturers have threatened litigation, arguing compounded substitutes pose risks from inconsistent manufacturing and dosing. The episode escalates tensions between telehealth/compounder business models and established pharma, raising questions about enforcement, supply chains and patient safety as appetite for GLP-1 therapies surges. Stakeholders are watching for rapid regulatory responses and potential civil suits that could set precedents for compounded versions of high-demand brand drugs.